Forecasting Fetal Buprenorphine Exposure through Maternal–Fetal Physiologically Based Pharmacokinetic Modeling
Open Access
- 8 March 2024
- journal article
- research article
- Published by MDPI AG in Pharmaceutics
- Vol. 16 (3) , 375
Abstract
Buprenorphine readily crosses the placenta, and with greater prenatal exposure, neonatal opioid withdrawal syndrome (NOWS) likely grows more severe. Current dosing strategies can be further improved by tailoring doses to expected NOWS severity. To allow the conceptualization of fetal buprenorphine exposure, a maternal–fetal physiologically based pharmacokinetic (PBPK) model for sublingual buprenorphine was developed using Simcyp (v21.0). Buprenorphine transplacental passage was predicted from its physicochemical properties. The maternal–fetal PBPK model integrated reduced transmucosal absorption driven by lower salivary pH and induced metabolism observed during pregnancy. Maternal pharmacokinetics was adequately predicted in the second trimester, third trimester, and postpartum period, with the simulated area under the curve from 0 to 12 h, apparent clearance, and peak concentration falling within the 1.25-fold prediction error range. Following post hoc adjustment of the likely degree of individual maternal sublingual absorption, umbilical cord blood concentrations at delivery (n = 21) were adequately predicted, with a geometric mean ratio between predicted and observed fetal concentrations of 1.15 and with 95.2% falling within the 2-fold prediction error range. The maternal–fetal PBPK model developed in this study can be used to forecast fetal buprenorphine exposure and would be valuable to investigate its correlation to NOWS severity.Keywords
Funding Information
- National Center for Advancing Translational Sciences (2UL1TR001425-05A1, 1P30HD106451)
- Maternal and Pediatric Precision in Therapeutics (MPRINT) Knowledge & Research Coordination Center (KRCC) of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) (2UL1TR001425-05A1, 1P30HD106451)
- Rieveschl/Parke-Davis Doctoral Candidacy Scholarship of the University of Cincinnati (2UL1TR001425-05A1, 1P30HD106451)
- Japan Research Foundation for Clinical Pharmacology (2UL1TR001425-05A1, 1P30HD106451)
This publication has 56 references indexed in Scilit:
- Physiologically‐Based Pharmacokinetic Modeling to Investigate the Effect of Maturation on Buprenorphine Pharmacokinetics in Newborns with Neonatal Opioid Withdrawal SyndromeClinical Pharmacology & Therapeutics, 2021
- Neonatal Abstinence Syndrome and Maternal Opioid-Related Diagnoses in the US, 2010-2017JAMA, 2021
- Prediction of maternal pharmacokinetics using physiologically based pharmacokinetic models: assessing the impact of the longitudinal changes in the activity of CYP1A2, CYP2D6 and CYP3A4 enzymes during pregnancyJournal of Pharmacokinetics and Pharmacodynamics, 2020
- Pharmacological Treatments for Neonatal Abstinence SyndromeJAMA Pediatrics, 2019
- The Pharmacokinetics and Pharmacodynamics of Buprenorphine in Neonatal Abstinence SyndromeClinical Pharmacology & Therapeutics, 2018
- Buprenorphine in Neonatal Abstinence SyndromeClinical Pharmacology & Therapeutics, 2017
- Differential Involvement of P-Glycoprotein (ABCB1) in Permeability, Tissue Distribution, and Antinociceptive Activity of Methadone, Buprenorphine, and Diprenorphine: In Vitro and In Vivo EvaluationJournal of Pharmaceutical Sciences, 2009
- Physiologically based pharmacokinetic modelling 2: Predicting the tissue distribution of acids, very weak bases, neutrals and zwitterionsJournal of Pharmaceutical Sciences, 2006
- Assessment of the hepatic arterial and portal venous blood flows during pregnancy with Doppler ultrasonographyArchives of Gynecology and Obstetrics, 2002
- Kinetics of intravenous and intramuscular morphineClinical Pharmacology & Therapeutics, 1978